key: cord-0912091-4ohjkxka authors: Sud, Amit; Jones, Michael; Broggio, John; Loveday, Chey; Torr, Bethany; Garrett, Alice; Nicol, David L.; Jhanji, Shaman; Boyce, Stephen A.; Gronthoud, Firza; Ward, Phillip; Handy, Jonathan M.; Yousaf, Nadia; Larkin, James; Suh, Yae-Eun; Scott, Stephen; Pharoah, Paul D.P.; Swanton, Charles; Abbosh, Christopher; Williams, Matthew; Lyratzopoulos, Georgios; Houlston, Richard; Turnbull, Clare title: Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic date: 2020-05-19 journal: Ann Oncol DOI: 10.1016/j.annonc.2020.05.009 sha: 372a10e95cb3369cb829e063d0c14e4b2fa74a61 doc_id: 912091 cord_uid: 4ohjkxka BACKGROUND: Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival. METHODS: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of three months and six months and periods of disruption of one year and two years. Using healthcare resource costing, we contextualise attributable lives saved and life-years gained from cancer surgery to equivalent volumes of COVID-19 hospitalisations. FINDINGS: Per year, 94,912 resections for major cancers result in 80,406 long-term survivors and 1,717,051 life years gained. Per-patient delay of three/six months would cause attributable death of 4,755/10,760 of these individuals with loss of 92,214/208,275 life-years. For cancer surgery, average life-years gained (LYGs) per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of three/six months (an average loss of 0.97/2.19 LYG per patient). Taking into account units of healthcare resource (HCRU), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of three/six months. For 94,912 hospital COVID-19 admissions, there are 482,022 LYGs requiring of 1,052,949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. INTERPRETATION: Modest delays in surgery for cancer incur significant impact on survival. Delay of three/six months in surgery for incident cancers would mitigate 19%/43% of life-years gained by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59% when considering resource-adjusted life-years gained. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued. Impact of COVID-associated delay on cancer outcomes 114 We used published data from studies examining the impact on overall survival from delay in 115 cancer surgery to estimate per day hazard ratios (HRs) associated with delay for different 116 cancers (the "Fatality HR") [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . We had sufficient data to generate Fatality HRs for three 117 tumour types and assigned these to other tumours, based on comparability of 5-year 118 survival as low (>90%) moderate (50-90%) or high (<50%) progressiveness tumours [5] . Because we were unable to identify any suitable observational data for tumours of high 120 progressiveness (e.g. oesophageal, gastric), we applied the Fatality HR from tumours of 121 moderate progressiveness; this is likely to be a conservative assumption (Supplementary 122 Table 2 ). By accounting for COVID-related post-surgical mortality and changes in SACT, we adjusted Impact of surgical delay on survival for different cancers 167 The greatest rates of deaths arise following even modest delays to surgery in aggressive 168 cancers, with over 30% reduction in survival at six months and over 17% reduction in 169 survival at three months for patients with stage 2 or 3 cancers of the bladder, lung, 170 oesophagus, ovary, liver, pancreas and stomach ( Table 4 ). In the context 185 of prioritisation, avoidance of a six-month delay restitutes on average 4.1 RALYGs in the 186 former group, compared to 0.7 in the latter ( Table 3, Supplementary Table 5 ). Wide local 187 excision for breast cancer has low resource requirement and therefore confers substantial 188 RALYGs, even in good prognosis subtypes. For aggressive cancers, our analysis demonstrates that even short delays (three months) 248 have a significant impact on patient survival. However, even for cancers of comparatively 249 favourable prognosis, a delay of six months will result in significant summed attributable 250 deaths as many of these cancers are common. Delay will also result in tumours being more 251 advanced, meaning not only is survival poorer, but that the upstaged cancers will be more 252 costly to treat both in terms of surgery and/or chemotherapy. Furthermore, resource 253 requirements (for example, ICU stay) are dramatically higher for the many who will Materials). Active focus is required to establish 'cold' sections of the healthcare system, 285 with rigorous protocols for staff screening and shielding protocols. This will serve to 286 minimise nosocomial acquisition and mortality from COVID-19, to protect staff, and also to 287 provide reassurance to the public regarding uptake of diagnostics and surgery for cancer. Given an accrued backlog of cases and ongoing tight competition for resources, decisions 295 regarding surgical prioritisation may be required for a number of years, with capacity 296 varying geographically and temporally. Recognising its limitations regarding assumptions 297 and parameters, we propose a model that provides a rational approach by which to 298 evaluate across patients of different ages, tumour types, and stages, the benefit and 299 resource implications of their cancer surgery. We highlight in our model those age-stage 300 groups for which COVID-related mortality currently exceeds survival benefit for surgery 301 and/or SACT. Whilst these and other groups for whom benefit is marginal will be the most 302 rationale to delay, they will nevertheless require monitoring and surgery downstream. Longitudinal planning, monitoring of progression, dynamic re-prioritisation, and capacity-304 planning will inevitably be highly challenging. Broader and International relevance 308 While we have used data for England, cancer survival is broadly similar across most 309 economically developed countries, so the impact of delay per tumour is broadly applicable 310 across Europe. However, variation in incidence of cancer, life expectancy and population 311 age structure mean that predictions regarding total case numbers and life-years gained and 312 lost are more difficult to extrapolate, even when scaling for relative size of reference 313 population. Whilst customised for surgical delay due to the COVID-19 pandemic, this model could 315 readily be adapted to quantify the impact of surgical delay due to other causes. Reduction in survival above the median is represented in red, at the median in yellow and below the median in green. Survival analysis is based on per-day hazard ratios for disease fatality. * indicates strata estimates of lower confidence whereby crude rather than net survival estimates were applied. !"" !""" !"""" !""""" Reduction in cancer referrals: Cancer Waits/Faster Diagnosis Standard data for West 419 London In A War on Two Fronts: Cancer Care in the Time 421 of COVID-19 Updated Intercollegiate General Surgery Guidance on COVID-19 Features of 16,749 hospitalised UK patients with 430 COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020 Effect of length of time from diagnosis to treatment on 436 colorectal cancer survival: A population-based study Influence of delay on survival in patients with 438 breast cancer: a systematic review 14. Smith EC, Ziogas A, Anton-Culver H. Delay in Surgical Treatment and Survival After Breast 443 Cancer Diagnosis in Young Women by Race/Ethnicity Delays in radical cystectomy for muscle-invasive bladder 445 cancer An interval longer than 12 weeks between the 447 diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma Significance of the time period between diagnosis of muscle 450 invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the 451 urothelium in the bladder Time to Surgery and Breast Cancer Survival in the 453 United States Effects of Delayed Surgical Resection on Short-Term and 455 Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. The Annals of Thoracic 456 Impact of Timing of Lobectomy on Survival for Clinical 458 Stage IA Lung Squamous Cell Carcinoma The influence on survival of delay in the 460 presentation and treatment of symptomatic breast cancer Routes to diagnosis for cancer -determining the 462 patient journey using multiple routine data sets /0,1023*,2++3.45+24-0,+) >)-)30?+2 29?03 B092-,?29?03 C0-29):2 D--,?29?03*